MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and ...

The approval was based on a bioavailability study comparing the efficacy of Zonisade oral suspension to zonisamide capsules in healthy individuals. The Food and Drug Administration (FDA) has approved ...

Novo Nordisk has stopped development of its next-generation oral GLP-1 analog OG2023SC. The Danish drugmaker took the action after making progress with an enhanced version of its existing oral ...

Bringing complex oral drugs to the clinic requires overcoming significant solubility, permeability, and bioavailability challenges. Many early-phase programs stall due to limited API supply, ...

SAN DIEGO, December 12, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE ® STIX (trofinetide) for ...

Anavex (AVXL) Life Sciences announced development of a once-daily oral tablet formulation for the ANAVEX3-71 program. The once-daily modified-release oral tablet exhibits superior pharmacokinetics ...

NEW YORK--(BUSINESS WIRE)--Laxxon Medical Corp., a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced that Veru Inc. (NASDAQ: ...

An analysis of data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database revealed differences in patterns of ocular events associated with oral and injectable ...

CURE Pharmaceutical Holding, which is developing oral dissolving film formulations of existing pharmaceutical drugs, announced terms for its IPO on Friday. Its stock is currently traded on the OTCQX ...